Cerecor Inc. (CERC) EPS Estimated At $-0.13

March 8, 2018 - By Michael Collier

 Cerecor Inc. (CERC) EPS Estimated At $ 0.13

Analysts expect Cerecor Inc. (NASDAQ:CERC) to report $-0.13 EPS on March, 13.They anticipate $0.05 EPS change or 27.78 % from last quarter’s $-0.18 EPS. After having $0.52 EPS previously, Cerecor Inc.’s analysts see -125.00 % EPS growth. The stock increased 9.90% or $0.51 during the last trading session, reaching $5.66. About 554,633 shares traded or 1.91% up from the average. Cerecor Inc. (NASDAQ:CERC) has declined 81.69% since March 8, 2017 and is downtrending. It has underperformed by 98.39% the S&P500.

Cerecor Inc. (NASDAQ:CERC) Ratings Coverage

Among 2 analysts covering Cerecor (NASDAQ:CERC), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Cerecor had 2 analyst reports since December 9, 2015 according to SRatingsIntel. Rodman & Renshaw downgraded Cerecor Inc. (NASDAQ:CERC) rating on Monday, December 12. Rodman & Renshaw has “Neutral” rating and $1 target. The firm has “Buy” rating by Laidlaw given on Wednesday, December 9.

Cerecor Inc., a clinical-stage biopharmaceutical company, develops drugs to treat patients with neurological and psychiatric disorders. The company has market cap of $176.82 million. It develops CERC-501, which has completed Phase II clinical trial for the adjunctive treatment of major depressive disorder , as well as to treat substance use disorders; CERC-301 that has completed Phase II clinical trial for the adjunctive treatment of patients with MDD; and CERC-406 that is in preclinical stage to treat residual cognitive impairment symptoms in patients with MDD. It has a 5.75 P/E ratio. Cerecor Inc. also intends to develop CERC-611, a drug candidate for the treatment of partial-onset seizures in epilepsy.

Another recent and important Cerecor Inc. (NASDAQ:CERC) news was published by Marketwired.com which published an article titled: “Cerecor to Acquire Avadel Pharmaceuticals’ Pediatric Assets” on February 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.